NCT05715736View on ClinicalTrials.gov

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3

PHASE1CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions

Still's Disease, Adult-Onset

Interventions

DRUG

APB-R3

APB-R3 is formulated as a sterile solution containing APB-R3 as the active substance administered intravenously.

DRUG

Placebo

0.90% Normal Saline only

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

AprilBio Co., Ltd.

INDUSTRY

lead

Syneos Health

OTHER